These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12232752)

  • 21. Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
    Kessler ER; Eckhardt SG; Pitts TM; Bradshaw-Pierce EL; O'byrant CL; Messersmith WA; Nallapreddy S; Weekes C; Spratlin J; Lieu CH; Kane MA; Eppers S; Freas E; Leong S
    Invest New Drugs; 2016 Apr; 34(2):176-83. PubMed ID: 26715573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial to evaluate gemcitabine and etoposide for locally advanced or metastatic pancreatic cancer.
    Melnik MK; Webb CP; Richardson PJ; Luttenton CR; Campbell AD; Monroe TJ; O'Rourke TJ; Yost KJ; Szczepanek CM; Bassett MR; Truszkowski KJ; Stein P; Van Brocklin MW; Davis AT; Bedolla G; Vande Woude GF; Koo HM
    Mol Cancer Ther; 2010 Aug; 9(8):2423-9. PubMed ID: 20682649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.
    Louvet C; André T; Lledo G; Hammel P; Bleiberg H; Bouleuc C; Gamelin E; Flesch M; Cvitkovic E; de Gramont A
    J Clin Oncol; 2002 Mar; 20(6):1512-8. PubMed ID: 11896099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.
    Song H; Han B; Park CK; Kim JH; Jeon JY; Kim IG; Kim HJ; Jung JY; Kim JH; Kwon JH; Jang G; Kim HY; Kim HS; Choi DR; Zang DY
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):845-52. PubMed ID: 23978987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
    Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ
    J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre.
    Ostwal V; Sahu A; Zanwar S; Nayak L; Shrikhande SV; Shetty N; Gupta S; Ramaswamy A
    Indian J Med Res; 2018 Sep; 148(3):284-290. PubMed ID: 30425218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
    Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer.
    Pericay Pijaume C; Escudero Emperador P; Bastús Piulats R; Campos Cervera JM; Esquerdo Galiana G; Gallén Castillo M; Alfaro Gamero J; Dotor Navarro E; Pisa Gatell A; Guasch Jordán I; Saigí Grau E;
    Clin Transl Oncol; 2011 Jan; 13(1):61-6. PubMed ID: 21239357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.
    El-Rayes BF; Zalupski MM; Shields AF; Vaishampayan U; Heilbrun LK; Jain V; Adsay V; Day J; Philip PA
    J Clin Oncol; 2003 Aug; 21(15):2920-5. PubMed ID: 12885810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.
    Lee J; Park JO; Kim WS; Lee SI; Song SY; Lim DH; Choi SH; Heo JS; Lee KT; Lee JK; Kim K; Jung CW; Im YH; Lee MH; Kang WK; Park K
    Oncology; 2004; 66(1):32-7. PubMed ID: 15031596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
    Boeck S; Hoehler T; Seipelt G; Mahlberg R; Wein A; Hochhaus A; Boeck HP; Schmid B; Kettner E; Stauch M; Lordick F; Ko Y; Geissler M; Schoppmeyer K; Kojouharoff G; Golf A; Neugebauer S; Heinemann V
    Ann Oncol; 2008 Feb; 19(2):340-7. PubMed ID: 17962204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy of gemcitabine combined oxaliplatin on advanced pancreatic cancer].
    Shi YX; Xu RH; Jiang WQ; Zhang L; Lin TY; Li YH; Xia ZJ; Luo HY; Han B; Wang F; He YJ; Guan ZZ
    Ai Zheng; 2007 Dec; 26(12):1381-4. PubMed ID: 18076807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
    Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ
    Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
    Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
    Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.
    El-Rayes BF; Philip PA; Sarkar FH; Shields AF; Ferris AM; Hess K; Kaseb AO; Javle MM; Varadhachary GR; Wolff RA; Abbruzzese JL
    Invest New Drugs; 2011 Aug; 29(4):694-9. PubMed ID: 20107864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival benefit with the combination of docetaxel, gemcitabine and erlotinib in advanced and/or metastatic pancreatic cancer patients.
    Samelis GF; Ekmektzoglou K; Tsiakou A; Giannakaki S; Konstadoulakis M
    Hepatogastroenterology; 2011; 58(110-111):1776-81. PubMed ID: 21940348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
    El-Rayes BF; Zalupski MM; Shields AF; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Adsay V; Philip PA
    Invest New Drugs; 2005 Dec; 23(6):583-90. PubMed ID: 16034525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma.
    Chiorean EG; Dragovich T; Hamm J; Barrios CH; Gorini CF; Langmuir VK; Kroll S; Jung DT; Tidmarsh GT; Loehrer PJ
    Am J Clin Oncol; 2010 Apr; 33(2):111-6. PubMed ID: 19687729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study.
    Endlicher E; Troppmann M; Kullmann A; Golder S; Herold T; Herfarth H; Grossmann J; Schlottmann K; Kullmann F
    Oncology; 2007; 72(5-6):279-84. PubMed ID: 18187949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
    Duffy A; Kortmansky J; Schwartz GK; Capanu M; Puleio S; Minsky B; Saltz L; Kelsen DP; O'Reilly EM
    Ann Oncol; 2008 Jan; 19(1):86-91. PubMed ID: 17878176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.